Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateTimeSourceHeadlineSymbolCompany
12/10/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
12/10/20244:30PMGlobeNewswire Inc.ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisNASDAQ:SLRNACELYRIN Inc
11/13/20245:26PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLRNACELYRIN Inc
11/13/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
11/13/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
11/13/20244:00PMGlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
11/08/20242:17PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
11/06/20244:00PMGlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024NASDAQ:SLRNACELYRIN Inc
11/04/20244:11PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
10/24/20242:02PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
10/16/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
09/19/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024NASDAQ:SLRNACELYRIN Inc
09/10/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive SurNASDAQ:SLRNACELYRIN Inc
08/22/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. to Participate in Upcoming Investor ConferencesNASDAQ:SLRNACELYRIN Inc
08/13/20244:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
08/13/20244:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
08/13/20244:00PMGlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial ResultsNASDAQ:SLRNACELYRIN Inc
08/06/20244:30PMGlobeNewswire Inc.ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024NASDAQ:SLRNACELYRIN Inc
06/11/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
06/05/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
05/29/20247:00AMGlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
05/28/20245:20PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
05/24/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/24/20247:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/24/20247:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/17/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/17/20247:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/17/20247:05PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
05/14/20244:22PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
05/09/20248:14AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN